8-K ·Filed May 20, 2026

ALKS

Alkermes plc.
NEUTRAL
Impact 3/10
Horizonweeks Processed4mo ago SEC0001193125-26-232584
8-K context-dependent: Items 5.02
Actionable Insight • Neutral

This is a routine governance filing with no immediate trading catalyst. Monitor future filings for actual equity grants under the expanded plan, which could indicate management's capital allocation priorities.

DirectionNeutral
Confidencehigh
Horizonweeks
Final — all horizons settled through T+60d
ALKS ▲ +34.93% at T+60d
NEUTRAL call ✓ call won +34.93% · α vs SPY +30.90% · entry $36.79 → $49.64
Entry anchored
May 20, 2026
via day open
T+1d
0.00%
call 0.00% · α -0.45%
$36.79
settled 4mo ago
T+5d
+14.03%
call +14.03% · α +12.18%
$41.95
settled 4mo ago
T+20d
+22.30%
call +22.30% · α +21.76%
$44.99
settled 4mo ago
T+60d
+34.93%
call +34.93% · α +30.90%
$49.64
settled 7w ago

Price Chart

Loading chart...

Executive Summary

Alkermes filed an 8-K reporting results of its 2026 annual meeting, where shareholders approved an amendment to the 2018 Stock Option and Incentive Plan to increase authorized shares by 5,900,000. All director nominees were elected, and non-binding advisory votes on executive compensation and auditor ratification passed.

Key Facts

  • Shareholders approved an amendment to increase shares reserved under the 2018 Stock Option and Incentive Plan by 5,900,000.
  • All nine director nominees were elected with large majorities (e.g., Shane M. Cooke: 135.5M for, 5.5M against).
  • Say-on-pay vote passed with 139.2M for, 1.8M against.
  • Ratification of PricewaterhouseCoopers as auditor passed with 146.2M for, 2.8M against.
  • Board authority to allot shares and disapply pre-emption rights under Irish law were renewed.

Financial Impact

The 5.9M share increase represents approximately 3.5% dilution relative to the current share count, but no shares are issued immediately.

dilution

Risk Factors

  • Potential future dilution from equity grants to employees and directors.
  • No material financial or operational changes reported.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
83% bullish (24 analysts)

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-232584
Document: alks-20260520.htm0001193125-26-232584
Document: 0001193125-26-232584-index-headers.html0001193125-26-232584
Document: 0001193125-26-232584-index.html0001193125-26-232584
Document: 0001193125-26-232584.txt0001193125-26-232584
18 reports for ALKS
Performance horizon
100% Hit rate 3 of 3 directional calls best @ T+60▲ +25.88%May 12, 2026
Filters
Rows
Reports for ALKS — sortable, filterable
TypeNow
Sep 16, 2026
16d ago
8-K
NEUTRAL ★ 2/10
$46.07 $42.13▼ −8.55%▼ −11.12%$41.75 (−9.38%)
Sep 3, 2026
28d ago
Insider Cluster
NEUTRAL ★ 2/10
$46.10 $45.83▼ −0.59%▲ +0.62%$41.75 (−9.44%)
Aug 3, 2026
8w ago
Insider Cluster
BEARISH ★ 4/10
$49.67 $49.21▲ +0.93%▲ +0.83%$41.75 (+15.95%)
Aug 3, 2026
8w ago
Insider Cluster
NEUTRAL ★ 2/10
$49.67 $49.21▼ −0.93%▼ −0.83%$41.75 (−15.95%)
Aug 3, 2026
8w ago
Insider Cluster
NEUTRAL ★ 3/10
$49.67 $49.21▼ −0.93%▼ −0.83%$41.75 (−15.95%)
Jul 28, 2026
9w ago
8-K
BEARISH ★ 6/10
$50.50 $49.53▲ +1.92%▲ +4.19%$41.75 (+17.33%)
Jul 8, 2026
12w ago
8-K
NEUTRAL ★ 3/10
$54.29 $51.60▼ −4.95%▼ −5.82%$41.75 (−23.10%)
Jul 6, 2026
12w ago
Insider Cluster
NEUTRAL ★ 2/10
$55.14 $51.94▼ −5.80%▼ −6.29%$41.75 (−24.28%)
Jun 4, 2026
17w ago
Insider Cluster
NEUTRAL ★ 3/10
$42.80 $44.28▲ +3.46%▲ +2.89%$41.75 (−2.45%)
Jun 1, 2026
17w ago
Insider Cluster
NEUTRAL ★ 2/10
$41.19 $44.29▲ +7.53%▲ +10.50%$41.75 (+1.37%)
Showing 10 of 18

US Market Status

Market Closed — Opens Mon (39h 26m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access